A new open-label clinical trial is investigating glasmacinal, an anti-inflammatory macrolide, in healthy adults. The focus is on how the drug impacts the community of microorganisms living in the human intestine. This reflects a growing trend in pharmacology: medicines are being evaluated not only for their direct effects on cells but also for how they reshape microbial ecosystems, which influence digestion, immunity, and metabolism. The study aims to identify biological signals and evaluate tolerability before larger controlled trials.
About the Author
